Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19

NCT04542213 is registered in ClinicalTrials.gov with Hospital Regional de Alta Especialidad del Bajio as lead sponsor.

NCT NCT04542213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04542213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19
Lead sponsor
Hospital Regional de Alta Especialidad del Bajio
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2020
Completion date
February 28, 2021
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, hyperglycemia